Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study (FEATS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The researchers aim to determine whether use of etonogestrel implant in patients with failed endometrial ablation significantly decreases hysterectomy rate. Changes in pelvic pain and vaginal bleeding will be assessed. Time to hysterectomy will be examined.
The researchers hypothesize that treatment of failed endometrial ablation with etonogestrel implant will decrease pelvic pain and vaginal bleeding resulting in a significantly decreased need for hysterectomy.
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Sarah N Smith, MD
- Phone Number: 306-352-4963
- Email: SarahSmith@saskhealthauthority.ca
Study Locations
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada
- Saskatchewan Health Authority
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Previous endometrial ablation
- Pelvic pain and/or vaginal bleeding seeking treatment
Exclusion Criteria:
- Previous or current VTE
- Liver tumour, benign or malignant, or active liver disease
- Undiagnosed abnormal genital bleeding
- Known or suspected breast cancer
- Uncontrolled hypertension
- Allergy to component of etonogestrel implant
- Lack of patient consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Etonogestrel implant
The participants will receive an etonogestrel 68mg implant
|
Implant will be inserted
Other Names:
Implant will be inserted
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hysterectomy
Time Frame: Occurrence of hysterectomy will be documented any time during the 3 year follow up period
|
occurrence of hysterectomy
|
Occurrence of hysterectomy will be documented any time during the 3 year follow up period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaginal bleeding
Time Frame: PBAC score will be documented at baseline and 3, 6, 12, 18, 24, 30, and 36 months
|
Pictorial Blood Loss Assessment Chart (PBAC) score, minimum score = 0mL, maximum score = n/a, higher score indicates higher menstrual blood loss
|
PBAC score will be documented at baseline and 3, 6, 12, 18, 24, 30, and 36 months
|
|
Pelvic Pain
Time Frame: VAS will be documented at baseline and 3, 6, 12, 18, 24, 30, and 36 months
|
Assessment of pelvic pain using Visual Analogue Scale (VAS), minimum score = 0, maximum score = 10, higher score indicates more pain
|
VAS will be documented at baseline and 3, 6, 12, 18, 24, 30, and 36 months
|
|
Time to Hysterectomy
Time Frame: Time of hysterectomy will be documented any time during the 3 year follow up period
|
Time from booking of hysterectomy to actual hysterectomy will be documented
|
Time of hysterectomy will be documented any time during the 3 year follow up period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sarah N Smith, MD, Obstetrician Gynecologist
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Neurologic Manifestations
- Pathologic Processes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Hemorrhage
- Pelvic Pain
- Uterine Hemorrhage
- Menstruation Disturbances
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain
- Dysmenorrhea
- Metrorrhagia
- Pharmaceutical Preparations
- Investigative Techniques
- Dosage Forms
- Genetic Phenomena
- Genetic Techniques
- Genetic Variation
- Protein Engineering
- Genetic Engineering
- Mutation
- Mutagenesis
- Delayed-Action Preparations
- Mutagenesis, Insertional
- etonogestrel
- Drug Implants
Other Study ID Numbers
Other Study ID Numbers
- REB-22-05
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.